Abstract
Objective
This study aimed to determine the effectiveness of short-term maintenance treatment with cabergoline and to find out minimum effective dosage of cabergoline during maintenance treatment for patients with microadenoma-related and idiopathic hyperprolactinemia.
Study design
Cabergoline was administered orally at a dose of 0.5 mg twice per week to 164 de novo hyperprolactinemic patients until serum prolactin level normalized. After this initial treatment phase, patients started on maintenance phase for which they were previously randomized. No maintenance treatment (Group I, n = 36) or cabergoline 0.5 mg (Group II, n = 46), 0.25 mg (Group III, n = 39), 0.125 mg (Group IV, n = 43) was administered twice per week for 8 weeks as maintenance treatment. Then, maintenance phase was finalized and patients were followed up for 6 months. Mean serum prolactin levels through maintenance treatment phase and follow-up period were assessed between groups and within groups.
Results
Except for group I, all the groups showed a similar pattern with fast decrease of serum prolactine level during maintenance phase and slower increase during the follow-up period. Notably, the average prolactin level was significantly lower at the last follow-up visit than at the diagnosis time in all of the groups. Stable normoprolactinemia of the groups at the end of follow-up period were 47.2, 37, 48.7, and 34.9%, respectively.
Conclusions
The results indicate that short maintanence treatment in idiopathic and microadenoma-related hyperprolactinemia seems as effective as long maintenance treatment in the present study. But, further studies with larger study population and longer follow-up period are needed to make a decision about early treatment withdrawal. Also, during the maintenance treatment adminisitration of medicine to patients should be tapered down to the lowest dose that will maintain prolactin levels normal.
Similar content being viewed by others
References
Biller BM, Luciano A, Crosignani PG et al (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 44(Suppl 12):1075–1084
Sluijmer AV, Lappohn RE (1992) Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 58:72–77
Mah PM, Webster J (2002) Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 20(4):365–373
Sharma JB, Roy KK, Mohanraj P, Kumar S, Karmakar D, Barua J (2009) Pregnancy outcome in pituitary tumors. Arch Gynecol Obstet 280:401–404
Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033
Verhelst J, Abs R, Maıter D, van den Bruel A, Vandeweghe M, Velkenıers B (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) For the cabergoline comparative study group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909
Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14:228–238
Vitale G, Di Sarno A, Rota F, Lombardi G, Colao A (2003) When can we stop cabergoline treatment in prolactinomas? Curr Opin Endocrinol Diabetes 10:259–264
Wass JA (2006) When to discontinue treatment of prolactinoma? Nat Clin Pract Endocrinol Metab 2(6):298–299
Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43–51
Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537–546
Ferrari C, Paracchi A, Mattei A, de Vincentiis S, D’Alberton A, Crosignani P (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126:489–494
Di Sarno A, Landi ML, Marzullo P et al (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53:53–60
Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94(7):2428–2436
Webster J, Piscitelli G, Polli A et al (1993) The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf) 39:323–329
Conflict of interest statement
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buyukbayrak, E.E., Karageyim Karsidag, A.Y., Kars, B. et al. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. Arch Gynecol Obstet 282, 561–566 (2010). https://doi.org/10.1007/s00404-010-1562-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-010-1562-6